• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙湿性年龄相关性黄斑变性的管理:在常规临床实践中治疗和推广实施面临的挑战

Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice.

作者信息

García-Layana A, García-Arumí J, Figueroa M S, Arias Barquet L, Ruíz-Moreno J M, Monclús-Arbona L

机构信息

Clínica Universidad de Navarra, Avenida de Pío XII 36, 31008 Pamplona, Spain.

Hospital de la Vall d'Hebrón, Passeig de la Vall d'Hebrón 119-129, 08035 Barcelona, Spain.

出版信息

J Ophthalmol. 2019 Sep 30;2019:9821509. doi: 10.1155/2019/9821509. eCollection 2019.

DOI:10.1155/2019/9821509
PMID:31662900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6791271/
Abstract

PURPOSE

To ascertain wet AMD (wAMD) management patterns in Spain.

METHODS

A two-round Delphi study conducted through a questionnaire-based survey designed from literature review and validated by an independent Steering Committee.

RESULTS

Forty-nine retina specialists experienced in wAMD participated by answering the two-round study questionnaire. Retina specialists are the main responsible for wAMD diagnosis and monitoring, including visits and associated procedures, with a median time per visit of 15 minutes. Standard treatment strategies are based on anti-VEGF administration, including standard loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients). Although treat and extend (T&E) dosing strategy is considered as optimal for wAMD management (78% of the panelists), the main routine healthcare limitations (i.e., visits overload, reduced staff, short visit time, coordination issues, lack of facilities) conduct to self-defined "flexible" strategies, based on T&E and pro-re-nata (PRN) protocols.

CONCLUSION

Proactive treatment patterns (T&E) are the preferred ones by the retina specialists in Spain. However, their proper implementation is difficult due to healthcare resource limitations, as well as organisation and logistic issues. The use of anti-VEGF agents with longer duration of action could facilitate the use of strict T&E approaches according to routine clinical practices.

摘要

目的

确定西班牙湿性年龄相关性黄斑变性(wAMD)的管理模式。

方法

通过两轮德尔菲研究进行,该研究通过基于文献综述设计并经独立指导委员会验证的问卷调查开展。

结果

49名在wAMD方面有经验的视网膜专家参与了两轮研究问卷的回答。视网膜专家主要负责wAMD的诊断和监测,包括就诊及相关程序,每次就诊的中位时间为15分钟。标准治疗策略基于抗血管内皮生长因子(VEGF)给药,包括标准负荷剂量给药,随后使用阿柏西普或雷珠单抗维持治疗(81%的患者)。尽管治疗并延长(T&E)给药策略被认为是wAMD管理的最佳策略(78%的小组成员),但主要的日常医疗保健限制(即就诊负担过重、工作人员减少、就诊时间短、协调问题、设施不足)导致基于T&E和按需(PRN)方案的自行定义的“灵活”策略。

结论

积极治疗模式(T&E)是西班牙视网膜专家的首选模式。然而,由于医疗资源限制以及组织和后勤问题,其正确实施存在困难。使用作用持续时间更长的抗VEGF药物可能有助于根据常规临床实践采用严格的T&E方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ff/6791271/30a51f09bf43/JOPH2019-9821509.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ff/6791271/30a51f09bf43/JOPH2019-9821509.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68ff/6791271/30a51f09bf43/JOPH2019-9821509.001.jpg

相似文献

1
Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice.西班牙湿性年龄相关性黄斑变性的管理:在常规临床实践中治疗和推广实施面临的挑战
J Ophthalmol. 2019 Sep 30;2019:9821509. doi: 10.1155/2019/9821509. eCollection 2019.
2
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.雷珠单抗和阿柏西普治疗及延长给药方案与按需给药方案治疗新生血管性年龄相关性黄斑变性的比较研究
Graefes Arch Clin Exp Ophthalmol. 2019 Sep;257(9):1889-1895. doi: 10.1007/s00417-019-04404-0. Epub 2019 Jun 29.
3
Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment.日本不同湿性年龄相关性黄斑变性抗VEGF治疗方案的医生、患者及护理人员体验:一项定性评估
Clin Ophthalmol. 2016 Dec 15;10:2505-2513. doi: 10.2147/OPTH.S120803. eCollection 2016.
4
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.玻璃体内阿柏西普与雷珠单抗治疗湿性年龄相关性黄斑变性的成本效果分析。
J Manag Care Spec Pharm. 2018 Jul;24(7):608-616. doi: 10.18553/jmcp.2018.24.7.608.
5
Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes.三种不同抗血管内皮生长因子治疗方案治疗新生血管性年龄相关性黄斑变性的有效性比较:两年真实世界临床结局
Clin Ophthalmol. 2021 Apr 23;15:1703-1713. doi: 10.2147/OPTH.S305141. eCollection 2021.
6
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.用于治疗新生血管性年龄相关性黄斑变性的抗血管内皮生长因子药物给药治疗方案。
Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2.
7
Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA.英国雷珠单抗治疗并延长用于新生血管性年龄相关性黄斑变性的资源使用及真实世界结局:TERRA研究的中期结果
Ophthalmol Ther. 2017 Jun;6(1):175-186. doi: 10.1007/s40123-017-0091-9. Epub 2017 May 15.
8
[Management of wet AMD in France in 2015].[2015年法国湿性年龄相关性黄斑变性的管理]
J Fr Ophtalmol. 2017 Nov;40(9):723-730. doi: 10.1016/j.jfo.2017.05.009. Epub 2017 Oct 18.
9
Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration.雷珠单抗治疗初诊新生血管性年龄相关性黄斑变性的策略比较
J Ocul Pharmacol Ther. 2017 Dec;33(10):773-778. doi: 10.1089/jop.2017.0006. Epub 2017 Sep 27.
10
[Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].德国新生血管性年龄相关性黄斑变性(AMD)患者抗VEGF治疗现状及疗效的回顾性调查:德国雷珠单抗治疗新生血管性AMD的治疗现状
Ophthalmologe. 2015 Mar;112(3):246-54. doi: 10.1007/s00347-014-3217-7.

引用本文的文献

1
Preferences of Hospital Pharmacists for the Different Attributes of Intravitreal Treatments for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Spain: The SEEKING Study.西班牙医院药剂师对新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿玻璃体内治疗不同属性的偏好:SEEKING研究
Pharmacy (Basel). 2025 May 14;13(3):68. doi: 10.3390/pharmacy13030068.
2
Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications.抗血管内皮生长因子药物治疗新生血管性年龄相关性黄斑变性:从作用机制到临床应用的进展
Front Med (Lausanne). 2024 Jul 19;11:1411278. doi: 10.3389/fmed.2024.1411278. eCollection 2024.
3

本文引用的文献

1
Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study.新生血管性年龄相关性黄斑变性治疗并延长给药方案与每月给药方案的随机试验:TREX-AMD研究的2年结果
Ophthalmol Retina. 2017 Jul-Aug;1(4):314-321. doi: 10.1016/j.oret.2016.12.004. Epub 2017 Feb 2.
2
Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States.美国抗血管内皮生长因子疗法治疗新生血管性年龄相关性黄斑变性的真实世界疗效
Ophthalmol Retina. 2018 Jul;2(7):645-653. doi: 10.1016/j.oret.2018.01.006. Epub 2018 Mar 1.
3
Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment.
地理萎缩管理共识(GA-MAC):关于识别、诊断和治疗的德尔菲小组研究。
BMJ Open Ophthalmol. 2023 Oct;8(1). doi: 10.1136/bmjophth-2023-001395.
4
Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration.新冠疫情封锁期间抗血管内皮生长因子治疗延迟的原因及对新生血管性年龄相关性黄斑变性的临床影响
Ophthalmol Ther. 2023 Oct;12(5):2537-2555. doi: 10.1007/s40123-023-00757-2. Epub 2023 Jul 4.
5
Impact of Routinely Performed Optical Coherence Tomography Examinations on Quality of Life in Patients with Retinal Diseases-Results from the ALBATROS Data Collection.常规光学相干断层扫描检查对视网膜疾病患者生活质量的影响——来自ALBATROS数据收集的结果
J Clin Med. 2023 Jun 7;12(12):3881. doi: 10.3390/jcm12123881.
6
Patient and retina specialists' preferences in neovascular age-related macular degeneration treatment. A discrete choice experiment.患者和视网膜专家在新生血管性年龄相关性黄斑变性治疗中的偏好。一项离散选择实验。
PLoS One. 2021 Dec 31;16(12):e0261955. doi: 10.1371/journal.pone.0261955. eCollection 2021.
7
Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea.玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性的真实世界结局:韩国的一项大规模上市后监测
Clin Ophthalmol. 2021 Aug 26;15:3601-3611. doi: 10.2147/OPTH.S324600. eCollection 2021.
8
A Randomized Study of Nutritional Supplementation in Patients with Unilateral Wet Age-Related Macular Degeneration.一项针对单侧湿性年龄相关性黄斑变性患者营养补充的随机研究。
Nutrients. 2021 Apr 10;13(4):1253. doi: 10.3390/nu13041253.
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group.
湿性年龄相关性黄斑变性中雷珠单抗治疗“治疗-延长”方案的启动与维持:英国视网膜结局小组的建议
Clin Ophthalmol. 2018 Sep 10;12:1731-1740. doi: 10.2147/OPTH.S174560. eCollection 2018.
4
Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial.使用阿柏西普治疗新生血管性年龄相关性黄斑变性的延长治疗:一项前瞻性临床试验。
Am J Ophthalmol. 2017 Aug;180:142-150. doi: 10.1016/j.ajo.2017.06.002. Epub 2017 Jun 15.
5
Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases.抗血管内皮生长因子治疗方案的基本原则:黄斑疾病玻璃体内抗血管内皮生长因子治疗的优化应用
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1259-1273. doi: 10.1007/s00417-017-3647-4. Epub 2017 May 19.
6
Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel.亚太地区玻璃体内注射阿柏西普采用治疗-延长方案治疗新生血管性年龄相关性黄斑变性的推荐指南:共识小组报告
Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):296-302. doi: 10.22608/APO.2016125. Epub 2017 Mar 29.
7
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.接受前期治疗的年龄相关性黄斑变性、糖尿病性黄斑水肿、视网膜静脉阻塞和近视性脉络膜新生血管患者的五年视力预后和注射模式。
Br J Ophthalmol. 2017 Mar;101(3):353-359. doi: 10.1136/bjophthalmol-2016-308668. Epub 2016 May 23.
8
Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts.湿性年龄相关性黄斑变性管理指南:希腊专家小组的建议
Adv Ther. 2016 May;33(5):715-26. doi: 10.1007/s12325-016-0332-7. Epub 2016 Apr 26.
9
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.现实生活中新生血管性年龄相关性黄斑变性视力提高的关键驱动因素:AURA研究结果
Br J Ophthalmol. 2016 Dec;100(12):1623-1628. doi: 10.1136/bjophthalmol-2015-308166. Epub 2016 Mar 30.
10
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.英国雷珠单抗治疗新生血管性年龄相关性黄斑变性的实际应用及疗效回顾性研究。
Clin Ophthalmol. 2016 Jan 13;10:87-96. doi: 10.2147/OPTH.S92627. eCollection 2016.